Bli medlem
Bli medlem

Du är här


AstraZeneca: AstraZeneca and MRC Laboratory of Molecular Biology to launch joint research fund

AstraZeneca today announced its intention to collaborate with the
Medical Research Council Laboratory of Molecular Biology (MRC LMB) to
fund a range of pre-clinical research projects aimed at better
understanding the biology of disease.

Projects supported by the fund are likely to involve scientists from
the two organisations working side by side, either within the MRC LMB
at the Cambridge Biomedical Campus, the site of the company's future
strategic R&D centre and global corporate headquarters, or in
AstraZeneca and MedImmune research facilities. As part of the planned
collaboration, AstraZeneca would contribute up to approximately £6
million ($10 million) and MRC LMB up to approximately £3 million ($5
million) over a period of five years, as well as in-kind scientific
input to share knowledge and technologies. Decisions on which
projects will receive support from the fund will be made jointly by
MRC LMB and AstraZeneca.

Menelas Pangalos, Executive Vice President of Innovative Medicines and
Early Development at AstraZeneca, said: "The aim of this joint fund
will be to encourage truly innovative scientific thinking. We want to
enable and encourage our scientists to push the boundaries of
science, on the door step of our Cambridge headquarters, with one of
the best scientific institutes in the world. Collaboration and
scientific exchange are at the heart of AstraZeneca's innovation-led
strategy, and this new fund will support our researchers to do
exactly that."

Sir Hugh Pelham, Director of the MRC LMB, said: "This is a very
exciting opportunity, in which AstraZeneca and the MRC LMB would be
able to share knowledge and resources to better understand the
fundamental processes that underlie normal function and disease. The
creation of a joint fund would further strengthen our existing and
long standing relationship with AstraZeneca, allowing our scientists
to work together, sharing ideas and expertise for the benefit of

Projects supported by the fund would be pre-competitive and would not
be specifically targeted towards drug development, but would feed
into the existing research and development activities of the two
organisations, with the results published in peer reviewed journals.

- ENDS -


About the MRC LMB

The Medical Research Council (MRC) Laboratory of Molecular Biology
(LMB) is one of the world's leading research institutes. Discoveries
and inventions developed at the LMB, for example DNA sequencing and
methods to determine the structure of proteins, have revolutionised
all areas of biology. Its scientists work to advance understanding
of biological processes at the molecular level. This information
will help us to understand the workings of complex systems, such as
the immune system and the brain, and solve key problems in human

About MedImmune

MedImmune is the worldwide biologics research and development arm of
AstraZeneca. MedImmune is pioneering innovative research and
exploring novel pathways across key therapeutic areas, including
respiratory, inflammation and autoimmunity; cardiovascular and
metabolic disease; oncology; neuroscience; and infection and
vaccines. The MedImmune headquarters is located in Gaithersburg, Md.,
one of AstraZeneca's three global R&D centres. For more information,
please visit

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of
cardiovascular, metabolic, respiratory, inflammation, autoimmune,
oncology, infection and neuroscience diseases. AstraZeneca operates
in over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information please visit:


AstraZeneca Media Enquiries

Esra Erkal-Paler +44 20 7604 8030 (UK/Global)

Vanessa Rhodes +44 20 7604 8037 (UK/Global)

Ayesha Bharmal +44 20 7604 8034 (UK/Global)

AstraZeneca Investor Enquiries

Karl Hård +44 20 7604 8123 mob: +44 7789 654364

Colleen Proctor +1 302 886 1842 mob: +1 302 357 4882

Anthony Brown +44 20 7604 8067 mob: +44 7585 404943

Jens Lindberg +44 20 7604 8414 mob: +44 7557 319729

MRC LMB Media Enquiries

Samantha Wynne +44 (0)1223 267223


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.